While it's straight forward to crunch the data for public companies that have to report their finances, it's not possible to do the same for biotech startups

Company Amount Raised Salix Pharmaceuticals (March) $690M Elan Corp. plc (March) $381M Theravance Inc. (April) $212.9M Amarin Corp. plc (January) $150M Vernalis plc (February) $103.8M ThromboGenics NV (March) $103.2M Horizon Pharma (March) $50.8M Algeta ASA (February) $45.4M Cytos Biotechnology (March) $40.6M Aastrom Biosciences (March) $40M

Public/other = Other financings of public companies, including loans, bridge financings, exercises of warrants, debt offerings, rights offerings, standard private placements, PIPE financings and institutional offerings of registered stock

Instead the public company recycles the proceeds from deal exits back into new opportunities...As a public company, Safeguard could use its stock to raise cash for further investments, but at this point Zarrilli said the $258 million in cash, cash equivalents and marketable securities it had at the end of 2011 is more than enough to make new capital deployments

Public companies felt the pinch slightly more than private companies: The total amount raised by the former dropped about 16 percent compared to the same period last year, while the total amount raised by the latter dropped about 8 percent...But beyond a handful of such large deals, the vast majority of the alternative fundraisings by public companies were small, with a median of just $5 million

Company Amount Raised Salix Pharmaceuticals (March) $690M Elan Corp. plc (March) $381M Amarin Corp. plc (January) $150M Vernalis plc (February) $103.8M ThromboGenics NV (March) $103.2M Horizon Pharma (March) $50.8M Algeta ASA (February) $45.4M Cytos Biotechnology (March) $40.6M Aastrom Biosciences (March) $40M Arena Pharmaceuticals Inc. (January) $28M

Public/other = Other financings of public companies, including loans, bridge financings, exercises of warrants, debt offerings, rights offerings, standard private placements, PIPE financings and institutional offerings of registered stock

Public companies felt the pinch slightly more than private companies: The total amount raised by the former dropped about 16 percent compared to the same period last year, while the total amount raised by the latter dropped about 8 percent...But beyond a handful of such large deals, the vast majority of the alternative fundraisings by public companies were small, with a median of just $5 million

Hicks said the loosening of the regulations is a realization that, following the Enron debacle, Congress "overlegislated the process of operating a public company

For instance, the JOBS Act would impact how the company could talk with investors, making life much easier once Regulus becomes a public company, Xanthopoulos said

Dara, a public company, has executed a number of public and private offerings of stock in order to raise money for ongoing operations

For instance, the JOBS Act would impact how the company could talk with investors, making life much easier once Regulus becomes a public company, Xanthopoulos said

The Menlo Park, Calif.-based biotech is unsure how to retain its mission in the face of an eventual future exit – Farzan noted that California is supportive of "flexible-purpose" public companies, while the right big pharma acquirer might also retain PaxVax's policy of forgoing profits in the developing world

Abingworth Bioventures and MPM Capital, which invest in both private and public companies, took stakes in Clovis and Verastem, respectively, even before their IPOs...Yet as Nodelman said, "we can debate valuation, but if every great private company did this, independent of stage, there would be more great public companies."

Company Amount Raised Amarin Corp. plc (January) $150M Vernalis plc (February) $103.8M Algeta ASA (February) $45.4M Arena Pharmaceuticals Inc. (January) $28M BioLineRx Ltd. (February) $15M Repros Therapeutics Inc. (January) $11.1M Talon Therapeutics Inc. (January) $11M

Public/other = Other financings of public companies, including loans, bridge financings, exercises of warrants, debt offerings, rights offerings, standard private placements, PIPE financings and institutional offerings of registered stock

Pharma companies favored public companies in their acquisitions, with 81 of 152 pharma-acquired companies being public at the time of acquisition

Pharma companies favored public companies in their acquisitions, with 81 of 152 pharma-acquired companies being public at the time of acquisition